Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.

Larimar Therapeutics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

* PRO FORMA CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES OF $203.6 MILLION REFLECTS $138.5 MILLION OF CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES AS OF JUNE 30, 2025 COMBINED WITH THE $65.1 MILLION IN NET PROCEEDS FROM THE RECENTLY COMPLETED JULY 2025 PUBLIC OFFERING.

LARIMAR THERAPEUTICS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS

BALA CYNWYD, PA., JULY 31, 2025 (GLOBE NEWSWIRE) -- LARIMAR THERAPEUTICS, INC. (LARIMAR) (NASDAQ: LRMR), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING TREATMENTS FOR COMPLEX RARE DISEASES, TODAY ANNOUNCED THE CLOSING OF ITS PREVIOUSLY ANNOUNCED UNDERWRITTEN PUBLIC OFFERING OF 21,562,500 SHARES OF ITS COMMON STOCK, WHICH INCLUDES THE EXERCISE IN FULL OF THE UNDERWRITERS' OPTION TO PURCHASE 2,812,500 ADDITIONAL SHARES, AT THE PUBLIC OFFERING PRICE OF $3.20 PER SHARE. THE AGGREGATE GROSS PROCEEDS TO LARIMAR FROM THIS OFFERING, BEFORE DEDUCTING UNDERWRITING DISCOUNTS AND COMMISSIONS AND OFFERING EXPENSES, WERE $69.0 MILLION.

LARIMAR THERAPEUTICS ANNOUNCES CLOSING OF UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK AND EXERCISE IN FULL OF THE UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL SHARES

BALA CYNWYD, PA., JULY 29, 2025 (GLOBE NEWSWIRE) -- LARIMAR THERAPEUTICS, INC. (LARIMAR) (NASDAQ: LRMR), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING TREATMENTS FOR COMPLEX RARE DISEASES, TODAY ANNOUNCED THE PRICING OF ITS PREVIOUSLY ANNOUNCED UNDERWRITTEN PUBLIC OFFERING OF 18,750,000 SHARES OF ITS COMMON STOCK AT A PRICE TO THE PUBLIC OF $3.20 PER SHARE. THE AGGREGATE GROSS PROCEEDS TO LARIMAR FROM THIS OFFERING ARE EXPECTED TO BE $60.0 MILLION, BEFORE DEDUCTING UNDERWRITING DISCOUNTS AND COMMISSIONS AND OTHER OFFERING EXPENSES. IN ADDITION, LARIMAR HAS GRANTED THE UNDERWRITERS A 30-DAY OPTION TO PURCHASE UP TO AN ADDITIONAL 2,812,500 SHARES OF ITS COMMON STOCK AT THE PUBLIC OFFERING PRICE, LESS UNDERWRITING DISCOUNTS AND COMMISSIONS. ALL SHARES OF COMMON STOCK ARE BEING OFFERED BY LARIMAR. THE OFFERING IS EXPECTED TO CLOSE ON OR ABOUT JULY 31, 2025, SUBJECT TO THE SATISFACTION OF CUSTOMARY CLOSING CONDITIONS.

LARIMAR THERAPEUTICS ANNOUNCES PRICING OF UNDERWRITTEN PUBLIC OFFERING

BALA CYNWYD, PA., JULY 29, 2025 (GLOBE NEWSWIRE) -- LARIMAR THERAPEUTICS, INC. (LARIMAR) (NASDAQ: LRMR), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING TREATMENTS FOR COMPLEX RARE DISEASES, TODAY ANNOUNCED THAT IT HAS COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF SHARES OF ITS COMMON STOCK AND, IN LIEU OF COMMON STOCK TO CERTAIN INVESTORS THAT SO CHOOSE, PRE-FUNDED WARRANTS TO PURCHASE SHARES OF ITS COMMON STOCK. IN ADDITION, LARIMAR EXPECTS TO GRANT THE UNDERWRITERS A 30-DAY OPTION TO PURCHASE UP TO AN ADDITIONAL 15% OF THE SECURITIES TO BE SOLD IN THE PROPOSED OFFERING AT THE PUBLIC OFFERING PRICE, LESS UNDERWRITING DISCOUNTS AND COMMISSIONS. ALL SHARES OF COMMON STOCK AND PRE-FUNDED WARRANTS IN THE PROPOSED OFFERING ARE TO BE SOLD BY LARIMAR. THE PROPOSED OFFERING IS SUBJECT TO MARKET AND OTHER CONDITIONS, AND THERE CAN BE NO ASSURANCE AS TO WHETHER OR WHEN THE OFFERING MAY BE COMPLETED, OR THE ACTUAL SIZE OR TERMS OF THE PROPOSED OFFERING.

LARIMAR THERAPEUTICS ANNOUNCES PROPOSED UNDERWRITTEN PUBLIC OFFERING

BALA CYNWYD, PA., JULY 08, 2025 (GLOBE NEWSWIRE) -- LARIMAR THERAPEUTICS, INC. (LARIMAR) (NASDAQ: LRMR), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING TREATMENTS FOR COMPLEX RARE DISEASES, TODAY ANNOUNCED THE PUBLICATION OF TWO PEER-REVIEWED ARTICLES HIGHLIGHTING NONCLINICAL DATA ON THE THERAPEUTIC POTENTIAL, PHARMACOLOGY, AND MECHANISM OF ACTION OF NOMLABOFUSP AS A NOVEL FRATAXIN (FXN) PROTEIN REPLACEMENT THERAPY DESIGNED TO ADDRESS THE UNDERLYING CAUSE OF FRIEDREICH'S ATAXIA (FA). THESE DATA WERE INCLUDED IN THE BRIEFING PACKAGE REVIEWED BY THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) IN SUPPORT OF POTENTIALLY USING SKIN FXN CONCENTRATIONS AS A REASONABLY LIKELY SURROGATE ENDPOINT (RLSE) FOR LARIMAR'S REGISTRATIONAL PROGRAM SEEKING ACCELERATED APPROVAL FOR NOMLABOFUSP.

LARIMAR THERAPEUTICS PUBLISHES NONCLINICAL DATA SUPPORTING THE THERAPEUTIC POTENTIAL OF NOMLABOFUSP IN PATIENTS WITH FRIEDREICH'S ATAXIA

INTERACTIONS WITH FDA OVER THE PAST YEAR HAVE PROVIDED CLEAR EXPECTATIONS FOR THE PATH TO SUBMISSION OF THE NOMLABOFUSP BLA WRITTEN FDA RECOMMENDATIONS FOR SAFETY DATABASE INCLUDE A TOTAL OF AT LEAST 30 PARTICIPANTS WITH CONTINUOUS EXPOSURE FOR 6 MONTHS INCLUDING A SUBSET OF AT LEAST 10 WITH 1-YEAR; LARGE MAJORITY OF THE EXPOSURE SHOULD BE ON THE 50 MG DOSE BLA SUBMISSION SEEKING ACCELERATED APPROVAL PLANNED IN THE SECOND QUARTER OF 2026 TO ALLOW FOR INCLUSION OF THE RECOMMENDED SAFETY DATA FOR ADULTS AND CHILDREN OLE DATA EXPECTED IN SEPTEMBER 2025 FROM 30-40 PARTICIPANTS WHO RECEIVED AT LEAST ONE DOSE OF NOMLABOFUSP; DATA WILL INCLUDE PARTICIPANTS ON THE 50 MG DOSE ADOLESCENT PK RUN-IN DATA EXPECTED IN SEPTEMBER 2025 FROM 14 PARTICIPANTS (SOME ON PLACEBO); PARTICIPANTS CURRENTLY SCREENING AND ENROLLING INTO OLE GLOBAL PHASE 3 STUDY ACTIVITIES ARE ONGOING WITH IDENTIFICATION AND QUALIFICATION OF SITES IN U.S., EUROPE, U.K., CANADA, AND AUSTRALIA COMPANY MANAGEMENT TO HOST WEBCAST AND CONFERENCE CALL TODAY AT 8:00 A.M. ET BALA CYNWYD, PA.

LARIMAR THERAPEUTICS ANNOUNCES FDA RECOMMENDATIONS ON SAFETY DATABASE, AND OTHER DETAILS OF NOMLABOFUSP BLA SUBMISSION FOR FRIEDREICH'S ATAXIA PROGRAM

BALA CYNWYD, PA., JUNE 20, 2025 (GLOBE NEWSWIRE) -- LARIMAR THERAPEUTICS, INC. (LARIMAR) (NASDAQ: LRMR), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING TREATMENTS FOR COMPLEX RARE DISEASES, TODAY ANNOUNCED THAT THE COMPANY WILL HOST A CONFERENCE CALL AND WEBCAST TO DISCUSS REGULATORY UPDATES FOR THE COMPANY'S NOMLABOFUSP CLINICAL DEVELOPMENT PROGRAM FOR THE TREATMENT OF FRIEDREICH'S ATAXIA ON MONDAY, JUNE 23, 2025 AT 8:00 AM EDT.

LARIMAR THERAPEUTICS ANNOUNCES REGULATORY UPDATE CALL ON THE NOMLABOFUSP PROGRAM FOR THE TREATMENT OF FRIEDREICH'S ATAXIA

FDA STATED AS PART OF A START PILOT PROGRAM MEETING THAT IT IS OPEN TO CONSIDERING SKIN FXN CONCENTRATION AS A REASONABLY LIKELY SURROGATE ENDPOINT IN SUPPORT OF AN ACCELERATED APPROVAL BLA SEEKING ACCELERATED APPROVAL PLANNED TO BE SUBMITTED BY YEAR-END 2025; GLOBAL PHASE 3 STUDY PLANNED TO INITIATE IN MID-2025 COMPLETED DOSING IN ADOLESCENT PK RUN-IN STUDY; TOPLINE 50 MG DOSE DATA FROM THE OLE STUDY AND DATA FROM ADOLESCENT COHORT PLANNED FOR PROGRAM UPDATE IN SEPTEMBER 2025 STRONG BALANCE SHEET OF $157.5 MILLION CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES AS OF MARCH 31, 2025, WITH PROJECTED CASH RUNWAY INTO SECOND QUARTER OF 2026 BALA CYNWYD, PA., APRIL 30, 2025 (GLOBE NEWSWIRE) -- LARIMAR THERAPEUTICS, INC. (LARIMAR) (NASDAQ: LRMR), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING TREATMENTS FOR COMPLEX RARE DISEASES,TODAY REPORTED ITS FIRST QUARTER 2025 OPERATING AND FINANCIAL RESULTS.

LARIMAR THERAPEUTICS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS

BALA CYNWYD, PA., MARCH 24, 2025 (GLOBE NEWSWIRE) -- LARIMAR THERAPEUTICS, INC. (LARIMAR) (NASDAQ: LRMR), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING TREATMENTS FOR COMPLEX RARE DISEASES,TODAY REPORTED ITS FOURTH QUARTER AND FULL YEAR 2024 OPERATING AND FINANCIAL RESULTS.

LARIMAR THERAPEUTICS PROVIDES NOMLABOFUSP DEVELOPMENT UPDATE AND REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS

BALA CYNWYD, PA., MARCH 03, 2025 (GLOBE NEWSWIRE) -- LARIMAR THERAPEUTICS, INC.(LARIMAR) (NASDAQ: LRMR), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING TREATMENTS FOR COMPLEX RARE DISEASES, TODAY ANNOUNCEDTHAT MEMBERS OF THE COMPANY'S MANAGEMENT TEAM WILL PRESENT AND PARTICIPATE IN 1X1 INVESTOR MEETINGS AT THE LEERINK PARTNERS GLOBAL HEALTHCARE CONFERENCE, TAKING PLACE IN MIAMI BEACH, FL FROM MARCH 10  12, 2025.

Larimar Therapeutics, Inc.

LRMR

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Larimar Therapeutics, Inc.

LRMR.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

LRMR